|
|
Article: Access Pharmaceuticals Provides Update on MuGard Commercial Launch and First European Clinicians Feedback.
- Article from:
- PR Newswire
- Article date:
- October 15, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
European Launch On Target - Initial Clinician And Patient Feedback Very Positive
DALLAS, Oct. 15 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (BULLETIN BOARD: ACCP) today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy. MuGard is commercially launched by Access' partner, SpePharm, in five European countries, having been granted the CE mak certification in October 2008 with the labeling "prevention and management of the lesions and symptoms of oral mucositis." SpePharm is currently gathering feedback from clinicians in the ...